Literature DB >> 15220217

Polymorphisms in type II SH2 domain-containing inositol 5-phosphatase (INPPL1, SHIP2) are associated with physiological abnormalities of the metabolic syndrome.

Pamela J Kaisaki1, Marc Delépine, Peng Y Woon, Liam Sebag-Montefiore, Steven P Wilder, Stephan Menzel, Nathalie Vionnet, Evelyne Marion, Jean-Pierre Riveline, Guillaume Charpentier, Stéphane Schurmans, Jonathan C Levy, Mark Lathrop, Martin Farrall, Dominique Gauguier.   

Abstract

Type II SH2 domain-containing inositol 5-phosphatase (INPPL1, or SHIP2) plays an important role in the control of insulin sensitivity. INPPL1 mutations affecting gene function have been found in rat models of type 2 diabetes and hypertension and in type 2 diabetic patients. We investigated the influence of nucleotide variation in INPPL1 on components of the metabolic syndrome. Following comprehensive resequencing of the gene, we genotyped 12 informative polymorphisms in 1,304 individuals from 424 British type 2 diabetes families that were characterized for several metabolic phenotypes. We have found highly significant associations of single nucleotide polymorphisms (SNPs) and haplotypes of INPPL1 with hypertension as well as with other components of the metabolic syndrome. In a cohort of 905 French type 2 diabetic patients, we found evidence of association of INPPL1 SNPs with the presence of hypertension. We conclude that INPPL1 variants may impact susceptibility to disease and/or to subphenotypes involved in the metabolic syndrome in some diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15220217     DOI: 10.2337/diabetes.53.7.1900

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  28 in total

1.  The inositol Inpp5k 5-phosphatase affects osmoregulation through the vasopressin-aquaporin 2 pathway in the collecting system.

Authors:  Eileen Pernot; Sara Terryn; Siew Chiat Cheong; Nicolas Markadieu; Sylvie Janas; Marianne Blockmans; Monique Jacoby; Valérie Pouillon; Stéphanie Gayral; Bernard C Rossier; Renaud Beauwens; Christophe Erneux; Olivier Devuyst; Stéphane Schurmans
Journal:  Pflugers Arch       Date:  2011-09-22       Impact factor: 3.657

2.  Diabetes quantitative trait locus research: from physiology to genetics and back.

Authors:  D Gauguier
Journal:  Diabetologia       Date:  2006-01-31       Impact factor: 10.122

Review 3.  Fig4 deficiency: a newly emerged lysosomal storage disorder?

Authors:  Colin Martyn; Jun Li
Journal:  Prog Neurobiol       Date:  2012-11-16       Impact factor: 11.685

4.  Locus and gene-based GWAS meta-analysis identifies new diabetic nephropathy genes.

Authors:  Mohammad Saeed
Journal:  Immunogenetics       Date:  2017-11-16       Impact factor: 2.846

Review 5.  INPPL1 gene mutations in opsismodysplasia.

Authors:  Anaïs Fradet; Jamie Fitzgerald
Journal:  J Hum Genet       Date:  2016-10-06       Impact factor: 3.172

Review 6.  Cellular and molecular interactions of phosphoinositides and peripheral proteins.

Authors:  Robert V Stahelin; Jordan L Scott; Cary T Frick
Journal:  Chem Phys Lipids       Date:  2014-02-17       Impact factor: 3.329

Review 7.  Rat models of human diseases and related phenotypes: a systematic inventory of the causative genes.

Authors:  Claude Szpirer
Journal:  J Biomed Sci       Date:  2020-08-02       Impact factor: 8.410

Review 8.  Insulin signaling regulating genes: effect on T2DM and cardiovascular risk.

Authors:  Sabrina Prudente; Eleonora Morini; Vincenzo Trischitta
Journal:  Nat Rev Endocrinol       Date:  2009-12       Impact factor: 43.330

9.  Aryl hydrocarbon receptor nuclear translocator-like (BMAL1) is associated with susceptibility to hypertension and type 2 diabetes.

Authors:  Peng Y Woon; Pamela J Kaisaki; José Bragança; Marie-Thérèse Bihoreau; Jonathan C Levy; Martin Farrall; Dominique Gauguier
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-29       Impact factor: 11.205

Review 10.  Phosphoinositides: tiny lipids with giant impact on cell regulation.

Authors:  Tamas Balla
Journal:  Physiol Rev       Date:  2013-07       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.